Gainers
- Tonix Pharmaceuticals, Inc. TNXP stock moved upwards by 65.7% to $0.67 during Wednesday's pre-market session.
- InflaRx, Inc. IFRX stock surged 15.8% to $4.84.
- Moderna, Inc. MRNA shares rose 11.3% to $26.44. The most recent rating by Bank of America, on December 03, is at Buy, with a price target of $29.00.
- Correvio Pharma, Inc. CORV shares increased by 11.1% to $0.40. According to the most recent rating by H.C. Wainwright, on December 11, the current rating is at Neutral.
- Guardion Health Sciences, Inc. GHSI shares moved upwards by 8.5% to $0.32.
- Alcon, Inc. ALC shares surged 7.9% to $63.45. The most recent rating by Morgan Stanley, on December 17, is at Overweight, with a price target of $70.00.
- Lipocine, Inc. LPCN stock surged 5.8% to $0.59.
- Amneal Pharmaceuticals, Inc. AMRX shares rose 5.0% to $5.00. The most recent rating by RBC Capital, on January 02, is at Sector Perform, with a price target of $4.00.
- Endo International, Inc. ENDP stock surged 4.9% to $6.85. The most recent rating by PiperJaffray, on January 03, is at Overweight, with a price target of $7.00.
- Mallinckrodt, Inc. MNK shares moved upwards by 4.2% to $4.95.
- ProQR Therapeutics, Inc. PRQR stock rose 3.6% to $8.00.
- Novavax, Inc. NVAX stock moved upwards by 3.1% to $8.20.
- Genprex, Inc. GNPX shares moved upwards by 2.7% to $6.40.
- Gilead Sciences, Inc. GILD stock surged 2.3% to $71.70. The most recent rating by Bernstein, on February 06, is at Market Perform, with a price target of $70.00.
- OPKO Health, Inc. OPK shares surged 2.2% to $1.42.
- Innate Pharma, Inc. IPHA shares rose 2.0% to $7.23.
- Massive Demand & Disruptive Potential – Boxabl has received interest for over 190,000 homes, positioning itself as a major disruptor in the housing market.
- Revolutionary Manufacturing Approach – Inspired by Henry Ford’s assembly line, Boxabl’s foldable tiny homes are designed for high-efficiency production, making homeownership more accessible.
- Affordable Investment Opportunity – With homes priced at $60,000, Boxabl is raising $1 billion to scale production, offering investors a chance to own a stake in its growth.
Losers
- SmileDirectClub, Inc. SDC stock plummeted 22.8% to $8.75 during Wednesday's pre-market session. The most recent rating by Wolfe Research, on January 09, is at Underperform, with a price target of $7.00.
- Spherix, Inc. SPEX stock fell 22.1% to $1.90.
- Cocrystal Pharma, Inc. COCP stock fell 8.2% to $2.01.
- TG Therapeutics, Inc. TGTX shares declined 5.8% to $13.35. The most recent rating by H.C. Wainwright, on January 17, is at Buy, with a price target of $24.00.
- Titan Pharmaceuticals, Inc. TTNP stock decreased by 4.5% to $0.21.
- Advaxis, Inc. ADXS shares decreased by 3.7% to $0.84.
- Catabasis Pharmaceuticals, Inc. CATB shares plummeted 3.5% to $4.70.
- Heat Biologics, Inc. HTBX shares decreased by 3.3% to $0.23. The most recent rating by Maxim Group, on February 06, is at Buy, with a price target of $1.00.
Loading...
Loading...
ALCAlcon Inc
$87.48-%
AMRXAmneal Pharmaceuticals Inc
$7.772.10%
COCPCocrystal Pharma Inc
$1.745.45%
GHSIGuardion Health Sciences Inc
$3.230.31%
GILDGilead Sciences Inc
$112.99-0.01%
GNPXGenprex Inc
$0.3050-1.29%
IFRXInflaRx NV
$0.8400-1.18%
IPHAInnate Pharma SA
$2.184.81%
LPCNLipocine Inc
$3.22-4.45%
MRNAModerna Inc
$27.90-0.85%
NVAXNovavax Inc
$7.420.13%
OPKOPKO Health Inc
$1.38-%
PRQRProQR Therapeutics NV
$1.935.42%
TGTXTG Therapeutics Inc
$39.75-0.23%
TNXPTonix Pharmaceuticals Holding Corp
$39.450.64%
TTNPTitan Pharmaceuticals Inc
$4.37-3.74%
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in